Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Ovarian Cancer – Access & Reimbursement – Access and Reimbursement – Ovarian Cancer (EU)
Market OutlookTargeted therapies are changing the treatment paradigm for ovarian cancer in the top 5 European markets (France, Germany, Italy, Spain, UK). Roche’s Avastin and small-molecule PARP…
Ovarian Cancer – Access & Reimbursement – Access & Reimbursement – Ovarian Cancer (US)
The premium-priced therapies used to treat ovarian cancer, such as Avastin (Roche/Genentech) and the PARP inhibitors Lynparza (AstraZeneca/Merck & Co), Rubraca (Clovis Oncology), and Zejula (…
Breast Cancer – Access & Reimbursement – Access & Reimbursement – Special Focus on Breast Cancer: Use of Clinical Pathways (US)
Market OutlookClinical pathways, which establish optimal treatment protocols for specific patient populations based on the best evidence, have become increasingly prevalent in the treatment of…
Niche and Rare Solid Tumors (Navigating Reimbursement and Maximizing Market Access) | Physician & Payer Forum | EU5 | 2015
A Survey of Medical Oncologists and Interviews with Payers in the EU5 Hepatocellular carcinoma (HCC), thyroid cancer, gastrointestinal stromal tumor (GIST), and neuroendocrine tumors (NETs) fall…